Current oncology最新文献

{"title":"Cutting Through History: The Evolution of Glioblastoma Surgery.","authors":"Abdullah H Ishaque, Sunit Das","doi":"10.3390/curroncol31110485","DOIUrl":"10.3390/curroncol31110485","url":null,"abstract":"<p><p>Despite significant advancements in neuro-oncology, management of glioblastoma remains a formidable challenge. Over the last century, the role and goals of surgery for patients with glioblastoma have evolved dramatically, with surgical intervention maintaining a central role in patient care. To understand the future role of surgery in the management of glioblastoma, we must review and appreciate the historical journey that has led us to this juncture. Here, we provide an overview of this evolution and speak about anticipated changes in the future. \"<i>Certainly we cannot hope to solve the glioblastoma problem by throwing up our hands and saying there is nothing we can do. On the contrary, the solution lies in our constantly pressing on, making more and more strenuous efforts to remove these tumors, and not allowing ourselves to be deterred by any obstacles that lie in our path.</i>\"-Ernest Sachs, 1950.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 11","pages":"6568-6576"},"PeriodicalIF":2.8,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11592654/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142726708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Efficacy of MRI-Based ADC Measurements in Detecting Axillary Lymph Node Metastasis: Evaluation of a Prospective Study.","authors":"Faruk Türkeş, Özcan Dere, Funda Dinç, Cenk Yazkan, Önder Özcan, Okay Nazlı","doi":"10.3390/curroncol31110487","DOIUrl":"10.3390/curroncol31110487","url":null,"abstract":"<p><p><b>Objective:</b> This study aimed to evaluate the efficacy of MRI-based Apparent Diffusion Coefficient (ADC) measurements in detecting axillary lymph node metastasis in breast cancer patients. By comparing preoperative MRI findings with intraoperative sentinel lymph node biopsy (SLNB) and postoperative pathological results, we sought to explore the potential of ADC values as a non-invasive alternative to axillary interventions. <b>Methods:</b> A total of 104 female patients diagnosed with breast cancer between 2019 and 2021 were included in this prospective study. ADC values of axillary lymph nodes, tumors, and muscle tissues were measured using a 3T MRI system. The correlation between these measurements and pathological outcomes was analyzed. Statistical analyses, including <i>t</i>-tests, ANOVA, and ROC curve analysis, were employed to assess the diagnostic performance of ADC values. <b>Results:</b> The results indicated that, while the mean ADC values of metastatic lymph nodes were lower than those of benign nodes, the sensitivity and specificity of MRI-based ADC measurements were inferior to the expected standards. The tumor ADC value and the tumor-to-lymph node ADC ratio were found to be more reliable indicators of metastasis than the lymph node ADC value alone. The diagnostic power of the tumor ADC value was significant, with a sensitivity of 75% and a specificity of 73%. <b>Conclusions:</b> MRI-based ADC measurements, particularly the tumor ADC value and the tumor-to-lymph node ADC ratio, show promise as potential non-invasive markers for axillary lymph node metastasis in breast cancer patients. However, the current results suggest that ADC measurements cannot yet replace SLNB in clinical practice.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 11","pages":"6598-6607"},"PeriodicalIF":2.8,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11592749/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142726665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Novel Oncogenic and Drug-Sensitive KIF5B-NTRK1 Fusion in Lung Adenocarcinoma.","authors":"Hui Li, Huicong Liu, Lisha Xiao, Huabin Gao, Huiting Wei, Anjia Han, Gengpeng Lin","doi":"10.3390/curroncol31110489","DOIUrl":"10.3390/curroncol31110489","url":null,"abstract":"<p><p>We present a case of a lung adenocarcinoma patient harboring a novel kinesin family member 5B (<i>KIF5B</i>)-<i>NTRK1</i> gene fusion that responds well to entrectinib. Moreover, <i>KIF5B</i>-<i>NTRK1</i> gene chimera has been shown to be an oncogene, activating both the MAPK and PI3K/AKT signaling pathways. The biopsy sample was analyzed using various methods such as hematoxylin-eosin staining (HE), immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS) based on a 1267-gene panel. Additionally, human lung adenocarcinoma cell lines A549 and H1755 were used to obtain a stable expression of chimera gene products. The cell proliferation was confirmed using CCK8 and adhesion-dependent colony formation assay. Cell invasion was confirmed using the transwell invasion assay. The protein levels of the MAPK and PI3K/AKT signaling pathways were assessed using Western blotting. The patient, a 66-year-old Chinese male, was diagnosed with adenocarcinoma (stage IVB) located in the upper lobe of the left lung. NGS analysis identified a novel <i>KIF5B</i>-<i>NTRK1</i> fusion gene, which was further confirmed by FISH and IHC analyses. As a first-line therapy, entrectinib was administered to the patient at a dose of 600 mg once daily, resulting in a partial response. The patient's progression-free survival (PFS) has now been more than 12 months, and no serious toxicities have been observed so far. Furthermore, stable KIF5B-NTRK1-expressing cells were generated and the experimental results demonstrate enhanced proliferation abilities, along with increased levels of proteins involved in the MAPK and PI3K/AKT signaling pathways. Our study reports a novel <i>KIF5B</i>-<i>NTRK1</i> genetic rearrangement that supports favorable responses to entrectinib. Moreover, in vitro experiments showed that the fusion gene could exert oncogenic properties by activating the MAPK and PI3K/AKT signaling pathways. To summarize, our findings broaden the spectrum of <i>NTRK</i> gene fusions in the context of lung adenocarcinoma.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 11","pages":"6621-6631"},"PeriodicalIF":2.8,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11593137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142726767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting Breast Cancer Relapse from Histopathological Images with Ensemble Machine Learning Models.","authors":"Ghanashyam Sahoo, Ajit Kumar Nayak, Pradyumna Kumar Tripathy, Amrutanshu Panigrahi, Abhilash Pati, Bibhuprasad Sahu, Chandrakanta Mahanty, Saurav Mallik","doi":"10.3390/curroncol31110486","DOIUrl":"10.3390/curroncol31110486","url":null,"abstract":"<p><p>Relapse and metastasis occur in 30-40% of breast cancer patients, even after targeted treatments like trastuzumab for HER2-positive breast cancer. Accurate individual prognosis is essential for determining appropriate adjuvant treatment and early intervention. This study aims to enhance relapse and metastasis prediction using an innovative framework with machine learning (ML) and ensemble learning (EL) techniques. The developed framework is analyzed using The Cancer Genome Atlas (TCGA) data, which has 123 HER2-positive breast cancer patients. Our two-stage experimental approach first applied six basic ML models (support vector machine, logistic regression, decision tree, random forest, adaptive boosting, and extreme gradient boosting) and then ensembled these models using weighted averaging, soft voting, and hard voting techniques. The weighted averaging ensemble approach achieved enhanced performances of 88.46% accuracy, 89.74% precision, 94.59% sensitivity, 73.33% specificity, 92.11% F-Value, 71.07% Mathew's correlation coefficient, and an AUC of 0.903. This framework enables the accurate prediction of relapse and metastasis in HER2-positive breast cancer patients using H&E images and clinical data, thereby assisting in better treatment decision-making.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 11","pages":"6577-6597"},"PeriodicalIF":2.8,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11592466/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142726841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two-Step Screening for Depression and Anxiety in Patients with Cancer: A Retrospective Validation Study Using Real-World Data.","authors":"Bryan Gascon, Joel Elman, Alyssa Macedo, Yvonne Leung, Gary Rodin, Madeline Li","doi":"10.3390/curroncol31110481","DOIUrl":"10.3390/curroncol31110481","url":null,"abstract":"<p><p><b>Background:</b> Although screening for distress is recommended by many cancer care guidelines, the uptake of such screening in cancer centers remains limited. Improving the acceptability of screening programs in cancer centers requires a reduction in clinical burden and an improved detection of distress. The purpose of this study was to validate the performance of the two-step screening algorithm used in the Distress Assessment and Response Tool (DART) for identifying cases of anxiety and depression. <b>Methods</b>: This retrospective validation study consisted of patients at the Princess Margaret Cancer Centre (PM) who completed the DART, which includes the Edmonton Symptom Assessment System depression (ESAS-D) and anxiety (ESAS-A) items, the Patient Health Questionnaire (PHQ-9), and the Generalized Anxiety Disorder (GAD-7). We evaluated the performance of a two-step screening approach, which modeled the ESAS-D, followed by the PHQ-9 and ESAS-A, then the GAD-7 for predicting a diagnosis of depression and anxiety disorders, respectively. A clinical psychiatric assessment was used as the gold standard reference. <b>Results:</b> A total of 172 patients with cancer were included in this study. A total of 59/172 (34%) and 39/172 (23%) were diagnosed with a depression or anxiety disorder, respectively. The sequential administration of the PHQ-9 ≥15 following the ESAS-D (>2) significantly increased the post-test probability of depression from 37% to 60% and improved the performance of predicting depression compared to both the ESAS-D or the PHQ-9 as standalone tests. The sequential administration of the GAD-7 after the ESAS-A did not improve the predictability of an anxiety diagnosis beyond the performance of the ESAS-A or the GAD-7 as standalone tests. <b>Conclusions:</b> The present study is among the first to demonstrate that a two-step screening algorithm for depression may improve depression screening in cancer using real-world data. Further research on optimal screening approaches for anxiety in cancer is warranted.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 11","pages":"6488-6501"},"PeriodicalIF":2.8,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11592598/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142726737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Esophagitis and Pneumonitis Related to Concurrent Chemoradiation ± Durvalumab Consolidation in Unresectable Stage III Non-Small-Cell Lung Cancer: Risk Assessment and Management Recommendations Based on a Modified Delphi Process.","authors":"Anthony M Brade, Houda Bahig, Andrea Bezjak, Rosalyn A Juergens, Charmaine Lynden, Nicolas Marcoux, Barbara Melosky, Devin Schellenberg, Stephanie Snow","doi":"10.3390/curroncol31110483","DOIUrl":"10.3390/curroncol31110483","url":null,"abstract":"<p><p>The addition of durvalumab consolidation to concurrent chemoradiation therapy (cCRT) has fundamentally changed the standard of care for patients with unresectable stage III non-small-cell lung cancer (NSCLC). Nevertheless, concerns related to esophagitis and pneumonitis potentially impact the broad application of all regimen components. A Canadian expert working group (EWG) was convened to provide guidance to healthcare professionals (HCPs) managing these adverse events (AEs) and to help optimize the patient experience. Integrating literature review findings and real-world clinical experience, the EWG used a modified Delphi process to develop 12 clinical questions, 30 recommendations, and a risk-stratification guide. The recommendations address risk factors associated with developing esophagitis and pneumonitis, approaches to risk mitigation and optimal management, and considerations related to initiation and re-initiation of durvalumab consolidation therapy. For both AEs, the EWG emphasized the importance of upfront risk assessment to inform the treatment approach, integration of preventative measures, and prompt initiation of suitable therapy in alignment with AE grade. The EWG also underscored the need for timely, effective communication between multidisciplinary team members and clarity on responsibilities. These recommendations will help support HCP decision-making related to esophagitis and pneumonitis arising from cCRT ± durvalumab and improve outcomes for patients with unresectable stage III NSCLC.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 11","pages":"6512-6535"},"PeriodicalIF":2.8,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11593044/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142726739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Factors for Patients with Small-Cell Lung Cancer Treated with Chemoimmunotherapy: A Retrospective Multicenter Study.","authors":"Takashi Hatori, Takeshi Numata, Toshihiro Shiozawa, Manato Taguchi, Hirofumi Sakurai, Tomohiro Tamura, Jun Kanazawa, Hiroaki Tachi, Kyoko Kondo, Kunihiko Miyazaki, Norihiro Kikuchi, Koichi Kurishima, Hiroaki Satoh, Nobuyuki Hizawa","doi":"10.3390/curroncol31110482","DOIUrl":"10.3390/curroncol31110482","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to investigate prognostic factors for predicting the survival of patients with extensive-disease-stage small-cell lung cancer treated with chemoimmunotherapy.</p><p><strong>Methods: </strong>Patients were classified according to overall survival (OS): favorable corresponded to an OS ≥ 24 months, moderate corresponded to an OS of 6-24 months, and poor corresponded to an OS < 6 months. Multivariate Cox regression analyses were used to evaluate prognostic factors.</p><p><strong>Results: </strong>Of 130 patients, the proportions of performance status decline and liver metastasis were significantly higher in the poor-prognosis group. With regard to the laboratory findings, neutrophil/lymphocyte ratios and albumin levels differed significantly among the groups. Multivariate analysis showed that the independent prognostic factors for OS were liver metastasis and decreased albumin levels (<3.5 mg/dL). After classifying the patients into three groups according to the quantities of these prognostic factors, the OS differed significantly among the groups (18.3 vs. 13.5 vs. 3.8 months; <i>p</i> < 0.001). The incidence of immune-related adverse events (irAEs) was higher in patients without these prognostic factors than in those with both (36% vs. 5%; <i>p</i> = 0.01).</p><p><strong>Conclusion: </strong>Liver metastasis and decreased albumin levels are independent unfavorable prognostic factors. Patients with both prognostic factors showed unfavorable OS; however, patients without these factors may have a favorable prognosis but be at greater risk of irAEs.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 11","pages":"6502-6511"},"PeriodicalIF":2.8,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11592429/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142726768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Outcome Patterns of Use of Radium-223 in Patients with Metastatic Castration-Resistant Prostate Cancer.","authors":"Colleen Mackenzie, Jasna Deluce, Morgan Black, Emma Churchman, Eric Winquist, Scott Ernst, David T Laidley, Matthew Parezanovic, Kylea Potvin, Ricardo Fernandes","doi":"10.3390/curroncol31110480","DOIUrl":"10.3390/curroncol31110480","url":null,"abstract":"<p><p><b>Introduction:</b> Radium-223 dichloride (radium-223) is a bone-targeting radioisotope therapy that aids in the survival of patients with metastatic castration-resistant prostate cancer (mCRPC) to bones. This study aimed to describe the clinical characteristics and outcomes of patients with mCRPC treated with radium-223 in a real-world setting. <b>Methods:</b> This was a retrospective study of patients with mCRPC treated with radium-223 between 2016 and 2020 at the London Health Sciences Centre in London, Canada. The baseline characteristics between the patients receiving 1-3 and 4-6 treatment cycles were compared using a two-sample t-test and Chi-square test. ANOVA was used to determine if there was a difference in each diagnostic variable per treatment cycle. Kaplan-Meier curves were generated to estimate progression-free survival (PFS) and overall survival in the patients treated with different numbers of cycles. <b>Results:</b> Fifty eligible patients were identified. The median age was 71 years (IQR: 66-76). Most patients (62%) received radium-223 beyond the third-line treatment. The mean number of radium-223 treatments was four. While 60% of the patients received 4-6 injections, 40% received 1-3 injections. Fifty-eight percent (58%) of the patients demonstrated a clinical benefit, with the remainder expressing either disease progression (28%) or stable disease (10%). The patients treated with 4-6 cycles had a delay to disease progression compared to those given 1-3 cycles of radium-223 (F_5,35 = 10.52, <i>p</i> < 0.001). A higher alkaline phosphatase level prior to treatment was associated with a longer PFS (z₃₃ = 2.362, <i>p</i> = 0.018). Treatment-related hospitalization for skeletal-related events was noted in 8% of the patients, and 14% required treatment discontinuation due to hematologic toxicity. <b>Conclusions:</b> This study confirms the safety of radium-223 in patients with mCRPC in a real-world setting. The radium-223 treatment was associated with a clinical benefit in the majority of the patients, particularly in those with higher pre-treatment serum alkaline phosphatase levels. Further studies to identify the predictive biomarkers are warranted to better guide the contemporary use of radium-223.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 11","pages":"6475-6487"},"PeriodicalIF":2.8,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11592830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142726560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lack of Association Between BsmI and FokI Polymorphisms of the VDR Gene and Sporadic Colorectal Cancer in a Romanian Cohort-A Preliminary Study.","authors":"Bianca Petre-Mandache, Emilia Burada, Mihai Gabriel Cucu, Diter Atasie, Anca-Lelia Riza, Ioana Streață, Radu Mitruț, Răzvan Pleșea, Amelia Dobrescu, Andrei Pîrvu, Gabriela Popescu-Hobeanu, Paul Mitruț, Florin Burada","doi":"10.3390/curroncol31100476","DOIUrl":"https://doi.org/10.3390/curroncol31100476","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is a major public health problem worldwide, currently ranking third in cancer incidence and second in mortality. Multiple genes and environmental factors have been involved in the complex and multifactorial process of CRC carcinogenesis. VDR is an intracellular hormone receptor expressed in both normal epithelial and cancer colon cells at various levels. Several VDR gene polymorphisms, including FokI and BsmI, have been evaluated for their possible association with CRC susceptibility. The aim of our study was to investigate these two SNPs for the first time in Romanian CRC patients. FokI (rs228570 C>T) and BsmI (rs1544410 A>G) were genotyped by real-time polymerase chain reaction (RT-PCR) in 384-well plates using specific TaqMan predesigned probes on a ViiA™ 7 RT-PCR System. A total of 441 subjects (166 CRC patients and 275 healthy controls) were included. No statistically significant difference was observed between CRC patients and controls when we compared the wild-type genotype with heterozygous and mutant genotypes for both FokI (OR 0.85, 95% CI: 0.56-1.28; OR 0.95, 95% CI: 0.51-1.79, respectively) and BsmI (OR 0.97, 95% CI: 0.63-1.49; OR 1.10, 95% CI: 0.65-1.87, respectively) or in the dominant and recessive models. Also, we compared allele frequencies, and no correlation was found. Moreover, the association between these SNPs and the tumor site, TNM stage, and histological type was examined separately, and there was no statistically significant difference. In conclusion, our study did not show any association between FokI and BsmI SNPs and CRC susceptibility in a Romanian population. Further studies including a larger number of samples are needed to improve our knowledge regarding the influence of VDR polymorphism on CRC susceptibility.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 10","pages":"6406-6418"},"PeriodicalIF":2.8,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11505952/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the Impact of the Prostate Cancer Patient Empowerment Program (PC-PEP) on Relationship Satisfaction, Quality of Life, and Support Group Participation: A Randomized Clinical Trial.","authors":"Cory Burgher, Gabriela Ilie, Ross Mason, Ricardo Rendon, Andrea Kokorovic, Greg Bailly, Nikhilesh Patil, David Bowes, Derek Wilke, Cody MacDonald, Markos Tsirigotis, Calvin Butler, David Bell, Jesse Spooner, Robert David Harold Rutledge","doi":"10.3390/curroncol31100479","DOIUrl":"10.3390/curroncol31100479","url":null,"abstract":"<p><p><b>Background/Objectives:</b> The Prostate Cancer Patient Empowerment Program (PC-PEP) is a 6-month, home-based intervention aimed at enhancing mental health in men undergoing curative prostate cancer treatment. This exploratory secondary analysis evaluates PC-PEP's impact on relationship satisfaction, quality of life, and support group attendance among partnered participants. <b>Methods:</b> In a crossover randomized clinical trial ClinicalTrials.gov identifier: NCT03660085) of 128 men aged 50-82 scheduled for curative prostate cancer surgery or radiotherapy, 119 participants in relationships were included. Of these, 59 received the 6-month PC-PEP intervention, while 60 were randomized to a waitlist-control arm, receiving standard care for 6 months before starting PC-PEP. The intervention included daily emails with video instructions on mental and physical health, diet, social support, fitness, stress reduction, and intimacy. Outcomes were assessed using the Dyadic Adjustment Scale (DAS) and the Functional Assessment of Cancer Therapy-Prostate (FACT-P). <b>Results:</b> While relationship satisfaction remained stable, a significant improvement in emotional well-being was observed at 12 months in participants undergoing radiation therapy (<i>p</i> = 0.045). The PC-PEP intervention also led to significantly higher support group attendance at both 6 months (<i>p</i> = 0.001) and 12 months (<i>p</i> = 0.003), emphasizing its role in fostering social support and community engagement. <b>Conclusions:</b> The PC-PEP program effectively maintains relationship satisfaction and enhances emotional well-being, particularly in patients with fewer physical side effects. Its design promotes comprehensive care by integrating physical, psychological, and social support, making it a valuable resource for improving the quality of life in prostate cancer patients and potentially applicable to other cancer types.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 10","pages":"6445-6474"},"PeriodicalIF":2.8,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11506086/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}